Literature DB >> 24014601

Circulating insulin-like factor 3 (INSL3) in healthy and infertile women.

R Anand-Ivell1, K Tremellen, Y Dai, K Heng, M Yoshida, P G Knight, G E Hale, R Ivell.   

Abstract

STUDY QUESTION: How does insulin-like factor 3 (INSL3) concentration in blood vary across the menstrual cycle in women? SUMMARY ANSWER: INSL3 is secreted by the theca interna cells of growing antral follicles and is phasic in its expression. WHAT IS KNOWN ALREADY: The relaxin-like hormone INSL3 is known to be expressed in follicles of several mammal species, and was recently shown in cows to be specifically secreted into the bloodstream by growing antral follicles, corresponding to follicular waves. In males INSL3 is known to be acutely independent of the hormones of the hypothalamic-pituitary-gonadal axis, suggesting that in women INSL3 might be a novel biomarker for antral follicle recruitment and development. STUDY DESIGN, SIZE, DURATION: Two cohorts of women were studied. First, 18 healthy women of reproductive age were followed longitudinally for one and a half cycles, with blood sampling and hormone measurement every 2-3 days. A second cohort comprised a cross-sectional study of 909 women attending an infertility clinic, with a single blood sample taken at entry, together with other clinical and hormonal parameters. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Blood samples from both retrospective cohorts were analyzed for INSL3 using a highly sensitive time-resolved fluorescent immunoassay, and data were analyzed in comparison with other clinical and hormonal parameters. MAIN RESULT AND THE ROLE OF CHANCE: For young healthy women of reproductive age, we showed a phasic expression of INSL3 corresponding to antral follicle growth in both the follicular and luteal phases of the cycle, which was significantly (P < 0.05) elevated compared with that during menses. For women attending an infertility clinic, those with diagnosed polycystic ovarian syndrome indicated significantly (P < 0.0005) greater circulating INSL3 levels and those with low ovarian reserve showed significantly (P < 0.002) decreased INSL3 values. LIMITATIONS, REASONS FOR CAUTION: These were retrospective studies and the results were obtained from natural cycles only, with their inherent variability. WIDER IMPLICATIONS OF THE
FINDINGS: We show for the first time that INSL3 in women does vary across the menstrual cycle, and appears to reflect the number of growing antral follicles recruited within both follicular and luteal phases. STUDY FUNDING/COMPETING INTEREST(S): The present retrospective study was largely supported by departmental funds. There were no competing interests.

Entities:  

Keywords:  INSL3; PCOS; antral follicle; human ovary; menstrual cycle

Mesh:

Substances:

Year:  2013        PMID: 24014601     DOI: 10.1093/humrep/det349

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  13 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Relaxin-like peptides in male reproduction - a human perspective.

Authors:  Richard Ivell; Alexander I Agoulnik; Ravinder Anand-Ivell
Journal:  Br J Pharmacol       Date:  2017-02-27       Impact factor: 8.739

3.  Diverse functions of insulin-like 3 peptide.

Authors:  Maria Esteban-Lopez; Alexander I Agoulnik
Journal:  J Endocrinol       Date:  2020-10-01       Impact factor: 4.286

4.  Perfluorooctane Sulfonate Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and Cryptorchidism and Hypospadias in Danish Boys (1980-1996).

Authors:  Gunnar Toft; Bo A G Jönsson; Jens Peter Bonde; Bent Nørgaard-Pedersen; David M Hougaard; Arieh Cohen; Christian H Lindh; Richard Ivell; Ravinder Anand-Ivell; Morten S Lindhard
Journal:  Environ Health Perspect       Date:  2015-06-05       Impact factor: 9.031

5.  Theca Cell INSL3 and Steroids Together Orchestrate the Growing Bovine Antral Follicle.

Authors:  Yanzhenzi Dai; Richard Ivell; Ravinder Anand-Ivell
Journal:  Front Physiol       Date:  2017-12-12       Impact factor: 4.566

Review 6.  Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology.

Authors:  Roshan Dadachanji; Nuzhat Shaikh; Srabani Mukherjee
Journal:  Genet Res Int       Date:  2018-02-18

Review 7.  Putative adverse outcome pathways for female reproductive disorders to improve testing and regulation of chemicals.

Authors:  Hanna K L Johansson; Pauliina Damdimopoulou; Majorie B M van Duursen; Julie Boberg; Delphine Franssen; Marijke de Cock; Kersti Jääger; Magdalena Wagner; Agne Velthut-Meikas; Yuling Xie; Lisa Connolly; Pauline Lelandais; Severine Mazaud-Guittot; Andres Salumets; Monica Kam Draskau; Panagiotis Filis; Paul A Fowler; Sofie Christiansen; Anne-Simone Parent; Terje Svingen
Journal:  Arch Toxicol       Date:  2020-07-07       Impact factor: 5.153

8.  The Male Fetal Biomarker INSL3 Reveals Substantial Hormone Exchange between Fetuses in Early Pig Gestation.

Authors:  Andreas Vernunft; Richard Ivell; Kee Heng; Ravinder Anand-Ivell
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

9.  Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin-Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results.

Authors:  Aylin Yetim; Çağcıl Yetim; Firdevs Baş; Oğuz Bülent Erol; Gülnaz Çığ; Ahmet Uçar; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-04-29

10.  Amniotic Fluid INSL3 Measured During the Critical Time Window in Human Pregnancy Relates to Cryptorchidism, Hypospadias, and Phthalate Load: A Large Case-Control Study.

Authors:  Ravinder Anand-Ivell; Arieh Cohen; Bent Nørgaard-Pedersen; Bo A G Jönsson; Jens-Peter Bonde; David M Hougaard; Christian H Lindh; Gunnar Toft; Morten S Lindhard; Richard Ivell
Journal:  Front Physiol       Date:  2018-04-24       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.